文献速递中毒与环境急症消化、代谢与肾脏急症

急诊科同伴支持对阿片类药物过量后治疗启动与结局的影响

Treatment Initiation and Outcomes Associated With Receipt of Emergency Department-Based Peer Support Following Opioid Overdose.
PubMed 文献 · Ann Emerg Med · 2025-08-06
一句话结论急诊科同伴康复支持项目与阿片类药物过量后180天内药物治疗启动率更高(15% vs 12%,HR=2.31)及全因急性医疗利用风险更低(HR=0.83)相关。

这项回顾性队列研究利用2015至2020年新泽西州医疗补助理赔数据与OORP评估数据,比较了参与急诊科同伴康复支持项目的阿片类药物过量事件与倾向评分匹配的非参与事件在180天随访期间的结局。共纳入5,475名患者的7,109次过量事件,其中参与组1,383次。参与组启动阿片类药物使用障碍药物治疗率更高(15% vs 12%;HR=2.31,95%CI 1.55-3.45),且药物治疗覆盖天数百分比更高(增加3.56个百分点,95%CI 0.72-6.47)、心理社会治疗启动(HR=1.73,95%CI 1.13-2.65)和参与(增加11.97个百分点,95%CI 7.23-16.73)更优,全因急性医疗利用风险更低(HR=0.83,95%CI 0.72-0.97)。项目与重复过量及阿片相关急诊或住院就诊的关联无统计学显著差异。结论认为同伴康复支持服务可支持急诊科治疗后的治疗衔接。

要点

  • 急诊科同伴康复支持项目参与组启动阿片类药物使用障碍药物治疗率15%,非参与组12%(HR=2.31,95%CI 1.55-3.45)。
  • 参与组药物治疗覆盖天数百分比更高,较非参与组增加3.56个百分点(95%CI 0.72-6.47)。
  • 参与组心理社会治疗启动HR=1.73(95%CI 1.13-2.65),参与度增加11.97个百分点(95%CI 7.23-16.73)。
  • 参与组全因急性医疗利用风险更低(HR=0.83,95%CI 0.72-0.97)。
  • 项目与重复过量及阿片相关急诊或住院就诊的关联无统计学显著差异。

适用人群与场景

  • 2015至2020年新泽西州医疗补助参保者中,急诊科治疗阿片类药物过量后的事件;参与组为参加OORP的过量事件,对照组为倾向评分匹配的非参与过量事件。

研究设计与关键结果

  • 回顾性队列研究,共纳入5,475名患者的7,109次过量事件(参与组1,383次);62.2%为男性,28.1%黑人、8.0%西班牙裔、56.1%白人,平均年龄40.1岁。
  • 参与组启动阿片类药物使用障碍药物治疗率15%,非参与组12%(HR=2.31,95%CI 1.55-3.45)。
  • 参与组药物治疗覆盖天数百分比较非参与组增加3.56个百分点(95%CI 0.72-6.47)。
  • 参与组心理社会治疗启动HR=1.73(95%CI 1.13-2.65),参与度增加11.97个百分点(95%CI 7.23-16.73)。
  • 参与组全因急性医疗利用风险更低(HR=0.83,95%CI 0.72-0.97)。
  • 项目与重复过量及阿片相关急诊或住院就诊的关联无统计学显著差异。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,同伴康复支持服务可支持急诊科治疗阿片类药物过量后的治疗衔接。
  • 作者指出,需要额外努力使患者长期留在阿片类药物使用障碍药物治疗中,以降低其重复过量风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVES: To examine whether participation in the New Jersey Opioid Overdose Recovery Program (OORP), an emergency department-based peer recovery support service, was associated with drug treatment initiation and other postdischarge outcomes.

METHODS: This retrospective cohort study used the 2015 to 2020 New Jersey Medicaid claims linked to OORP evaluation data. Outcomes during 180-day follow-up were compared between opioid overdoses among OORP participants and a propensity score-matched group of overdoses among nonparticipants. Outcomes included any medication for opioid use disorder initiation (primary), percentage of days covered with medication for opioid use disorder, psychosocial treatment initiation and engagement, repeat opioid and any drug overdose, and all-cause and opioid-related acute care utilization. Outcomes were assessed using linear regression (for medication for opioid use disorder percentage of days covered and psychosocial treatment engagement) and Cox proportional hazards (for all other outcomes) models.

RESULTS: A total of 7,109 overdose events among 5,475 patients were included (62.2% men; 28.1% Black, 8.0% Hispanic, 56.1% White; mean age: 40.1 years). OORP participants (N=1,383 events) initiated medication for opioid use disorder at higher rates than nonparticipants (15% versus 12%; hazard ratio [HR]=2.31, 95% confidence interval [CI] 1.55 to 3.45). OORP participation was also associated with greater medication for opioid use disorder percentage of days covered (3.56 percentage points, 95% CI 0.72 to 6.47), psychosocial treatment initiation (HR=1.73, 95% CI 1.13 to 2.65), and psychosocial treatment engagement (11.97 percentage points, 95% CI 7.23 to 16.73), and lower risk of all-cause acute care utilization (HR=0.83; 95% CI 0.72 to 0.97). The association of the program with repeat overdose and opioid-related ED or inpatient visits was not statistically significant.

CONCLUSION: Peer recovery support service can support treatment linkages following ED-treated opioid overdose. Additional efforts are needed to retain patients in medication for opioid use disorder long-term, to reduce their risk for repeat overdose.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Treitler P, Lloyd K, Cantor J, et al. Treatment Initiation and Outcomes Associated With Receipt of Emergency Department-Based Peer Support Following Opioid Overdose. Ann Emerg Med. 2025. PMID: 40767797. doi:10.1016/j.annemergmed.2025.06.616

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。